Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Safety Run-in Part -To establish a safe and tolerable dose of azacitidine to be used in the randomized part of the study. Randomized Part -To evaluate the effect of azacitidine treatment in AML subjects at molecular relapse after CR1 when compared to no treatment with regard to the progression-free rate (PFR) at Day 84 (±4 days) postrandomization.
Critère d'inclusion
- Treatment of children and young adults with molecular relapse of acute myeloid leukemia
- (AML) after first complete remission (CR1)